Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LAGOON trial of lurbinectedin with or without irinotecan versus investigator's choice in relapsed small cell lung cancer
2021-004471-13Phase 3Active
- Sponsor
- PharmaMar
- Start
- Mar 2022
- Modality
- Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of lurbinectedin, irinotecan and topotecan in small cell lung cancer (SCLC) (3 arms), sponsored by PharmaMar. Primary endpoint: Overall survival. Started Mar 2022; status: active.
02
Drugs
lurbinectedinirinotecantopotecan
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on 2021-004471-13.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-004471-13.